The Indian Patent Office has denied a secondary patent for AbbVie's Hepatitis C drug Maviret. This decision ensures continued access to affordable treatment for millions. The patent office refused the application after AbbVie failed to contest oppositions and… For the full story, visit the source.
BusinessDelhi
AbbVie loses patent plea for Hep C drug
The Indian Patent Office has denied a secondary patent for AbbVie's Hepatitis C drug Maviret. This decision ensures continued access to affordable treatment for millions. The patent office refused the application after AbbVie failed to contest oppositions and…
By Teena Thacker· The Times of India· 5 months ago· 2 min read
This summary is sourced from The Times of India. Read the full article at:The Times of India